CTOs on the Move

54gene

www.54gene.com

 
54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.54gene.com
  • 1100 15th Street North West
    Washington, DC USA 20005
  • Phone: n/a

Executives

Name Title Contact Details

Funding

54gene raised $15M on 04/14/2020

Similar Companies

Tmunity

Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)

Accurate Automation

Accurate Automation Corp. is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChemCross.com

ChemCross.com is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Akron Biotechnology

Akron Biotechnology is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IconOVir

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O`Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.